Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in...
KENILWORTH, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE:SGP) announced today the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the...
CHICAGO, Oct. 30 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for CSCO, SGP, BHP, COST, and AEO. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
KENILWORTH, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP) today announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be...
BOXMEER, Netherlands, Oct. 8 /PRNewswire-FirstCall/ -- Intervet/Schering-Plough Animal Health today announced that it has initiated a multi-year sponsorship project, supporting the Shire...
CHICAGO, Oct. 7 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MSFT, SGP, AUY, WFMI, and ACH. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today announced that its investigational agent SAPHRIS(R) (asenapine) met the primary endpoint over one...
KENILWORTH, N.J., July 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported a proposed settlement, subject to Court approval, to resolve litigation seeking to...
KENILWORTH, N.J., July 22 /PRNewswire-FirstCall/ -- Schering-Plough today announced that a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate...
Single-dose of investigational sustained follicle stimulant achieves similar efficacy to daily injections of follitropin beta given over a one week period in Phase III Study AMSTERDAM, July 1...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
